Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine (PCV13) when given as a toddler dose to children immunized with PCV7 as infants

被引：27
作者：
Grimprel, E. [1 ,2 ]
Laudat, F. [3 ]
Patterson, S. [4 ]
Baker, S. A. [3 ]
Sidhu, M. S. [3 ]
Gruber, W. C. [3 ]
Emini, E. A. [4 ]
Scott, D. A. [3 ]
机构：
[1] Univ Paris 06, F-75252 Paris 05, France
[2] Hop Armand Trousseau, Serv Pediat Gen, F-75012 Paris, France
[3] Pfizer Inc, Vaccine Res, Pearl River, NY USA
[4] Pfizer Inc, Collegeville, PA USA
来源：
VACCINE | 2011年 / 29卷 / 52期
关键词：
Safety; Immunogenicity; 13-Valent pneumococcal conjugate vaccine; 7-Valent pneumococcal conjugate vaccine; Toddler dose; Infants; OPSONOPHAGOCYTIC ASSAY; YOUNG-CHILDREN; DOUBLE-BLIND; DISEASE; PNEUMONIA; EFFICACY; 9-VALENT; REACTOGENICITY; TOLERABILITY; SERIES;
D O I：
10.1016/j.vaccine.2011.10.012
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
13-Valent pneumococcal conjugate vaccine (PCV13) administered as a 4-dose series in infants, and as a toddler dose in infants previously vaccinated with PCV7 elicited comparable vaccine serotypes IgG responses to the seven common serotypes. PCV13 elicited functional responses to the six additional serotypes in both schedules after the toddler dose. The toddler dose boosted immune responses. The two regimens had comparable safety profiles. A toddler dose of PCV13 given in children previously vaccinated with PCV7 should be effective in preventing pneumococcal disease caused by common serotypes, providing protection against the additional serotypes, and supporting the transition from PCV7 to PCV13. (C) 2011 Published by Elsevier Ltd.
引用
收藏
页码：9675 / 9683
页数：9
相关论文
共 42 条
[1]  
Addae-Mensah I, 2005, WHO TECH REP SER, V929, P1
[2]  
[Anonymous], 2007, Wkly Epidemiol Rec, V82, P93
[3]  
Baker S., 2006, 5 INT S PNEUM PNEUM, P285
[4]   Pneumococcal necrotizing pneumonia in utah: Does serotype matter? [J].
Bender, Jeffrey M. ;
Ampofo, Krow ;
Korgenski, Kent ;
Daly, Judy ;
Pavia, Andrew T. ;
Mason, Edward O. ;
Byington, Carrie L. .
CLINICAL INFECTIOUS DISEASES, 2008, 46 (09) :1346-1352
[5]   Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children [J].
Black, S ;
Shinefield, H ;
Fireman, B ;
Lewis, E ;
Ray, P ;
Hansen, JR ;
Elvin, L ;
Ensor, KM ;
Hackell, J ;
Siber, G ;
Malinoski, F ;
Madore, D ;
Chang, I ;
Kohberger, R ;
Watson, W ;
Austrian, R ;
Edwards, K .
PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2000, 19 (03) :187-195
[6]   Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomised, double-blind, placebo-controlled trial [J].
Cutts, FT ;
Zaman, SMA ;
Enwere, G ;
Jaffar, S ;
Levine, OS ;
Okoko, JB ;
Oluwalana, C ;
Vaughan, A ;
Obaro, SK ;
Leach, A ;
McAdam, KP ;
Biney, E ;
Saaka, M ;
Onwuchekwa, U ;
Yallop, F ;
Pierce, NF ;
Greenwood, BM ;
Adegbola, RA .
LANCET, 2005, 365 (9465) :1139-1146
[7]   Efficacy of a pneumococcal conjugate vaccine against acute otitis media [J].
Eskola, J ;
Kilpi, T ;
Palmu, A ;
Jokinen, J ;
Haapakoski, J ;
Herva, E ;
Takala, A ;
Käyhty, H ;
Karma, P ;
Kohberger, R ;
Siber, G ;
Mäkela, PH ;
Lockhart, S ;
Ecrola, M .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (06) :403-409
[8]   Immunogenicity, safety and tolerability of heptavalent pneumococcal conjugate vaccine administered at 3, 5 and 11 months post-natally to pre- and full-term infants [J].
Esposito, S ;
Pugni, L ;
Bosis, S ;
Proto, A ;
Cesati, L ;
Bianchi, C ;
Cimino, C ;
Mosca, F ;
Principi, N .
VACCINE, 2005, 23 (14) :1703-1708
[9]   Safety and Immunogenicity of a 13-Valent Pneumococcal Conjugate Vaccine Compared to Those of a 7-Valent Pneumococcal Conjugate Vaccine Given as a Three-Dose Series with Routine Vaccines in Healthy Infants and Toddlers [J].
Esposito, Susanna ;
Tansey, Susan ;
Thompson, Allison ;
Razmpour, Ahmad ;
Liang, John ;
Jones, Thomas R. ;
Ferrera, Giuseppe ;
Maida, Alessandro ;
Bona, Gianni ;
Sabatini, Caterina ;
Pugni, Lorenza ;
Emini, Emilio A. ;
Gruber, William C. ;
Scott, Daniel A. ;
Principi, Nicola .
CLINICAL AND VACCINE IMMUNOLOGY, 2010, 17 (06) :1017-1026
[10]  
Fritzell B, 2011, EXPERT REV VACCINES, V10, P263, DOI [10.1586/erv.11.11, 10.1586/ERV.11.11]
12345